Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | FABP7 | O15540 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1073550 | 1.00 | EPHX1 (0.36) | EPHX1CYP2C19NAAALMNAFABP7 | |
| SCHEMBL1072710 | 0.83 | EPHX1 (0.36) | EPHX1CYP2C19NAAALMNAFABP7 | |
| SCHEMBL4989860 | 0.81 | EPHX1 (0.37) | EPHX1CYP2C19NAAALMNAFABP7 | |
| SCHEMBL4989852 | 0.81 | EPHX1 (0.37) | EPHX1CYP2C19NAAALMNAFABP7 | |
| SCHEMBL1150119 | 0.81 | EPHX1 (0.39) | EPHX1CYP2C19NAAALMNAFABP7 | |
| SCHEMBL1073412 | 0.81 | LMNA (0.39) | LMNA | |
| SCHEMBL1150124 | 0.81 | EPHX1 (0.39) | EPHX1CYP2C19NAAALMNAFABP7 | |
| SCHEMBL1150121 | 0.81 | EPHX1 (0.39) | EPHX1CYP2C19NAAALMNAFABP7 | |
| SCHEMBL1073410 | 0.81 | LMNA (0.39) | LMNA | |
| SCHEMBL22931823 | 0.77 | HPGD (0.46) | EPHX1CYP2C19NAAALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797953-B1 | PROCESS FOR PRODUCING OXYGENIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20080064898-A1 | Method for Producing Oxygen-Containing Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1797953-A1 | PROCESS FOR PRODUCING OXYGENIC COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064898-A1 | Method for Producing Oxygen-Containing Compound | AOC2, AOX1, CAT | EPHX1 321/4885CYP2C19 638/4885NAAA 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.